AMY109
AMY109 is an anti-human interleukin-8 (IL-8) monoclonal antibody, with a Ka of 36.8 pM for human IL-8, and a Ka of 380 pM for cynomolgus monkey IL-8. AMY109 binds to human and cynomolgus monkey IL-8 in a pH-dependent manner, inhibits IL-8-mediated activation of CXCR1 and CXCR2, and blocks the downstream biological activities of IL-8. AMY109 inhibits neutrophil recruitment to endometriotic lesions and suppresses monocyte chemoattractant protein-1 production by neutrophils. AMY109 is applicable to research related to endometriosis.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Human
AMY109 (pH 7.4; pH 5.8) exhibits high binding affinity to human IL-8 and weaker but measurable binding affinity to cynomolgus monkey IL-8 under neutral conditions, with pH-dependent dissociation from human IL-8 at endosomal pH[1].
AMY109 potently neutralizes IL-8-dependent activation of both CXCR1 and CXCR2 in cell-based assays[1].
AMY109 (600 ng/mL IL-8) effectively inhibits IL-8-induced chemotaxis of both human and cynomolgus monkey neutrophils[1].
AMY109 inhibits both IL-8-induced human neutrophil migration and IL-8-stimulated MCP-1 production by human neutrophils[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Macaca fascicularis (female, reproductive age 8 to 14 years old, surgically induced endometriosis)[1]
-
Dosage:2 mg/kg (maintenance dose; preceded by a 3 mg/kg loading dose); 10 mg/kg
-
Administration:subcutaneous injection; every 4 weeks; 6 months
-
Result:Maintained modified r-ASRM score stable, while it significantly increased in vehicle-treated monkeys.
Reduced relative volume of nodular lesions.
Induced atrophy of endometrial epithelium in 55% of evaluable sites (2 mg/kg) and 54% of evaluable sites (10 mg/kg).
Induced atrophy/decreased stromal cells in 33% of evaluable sites (2 mg/kg) and 60% of evaluable sites (10 mg/kg).
Decreased fibrotic interstitium in 34% of evaluable sites (2 mg/kg) and 61% of evaluable sites (10 mg/kg).
Reduced hemosiderin deposition compared to vehicle.
Produced marked reduction in postsurgical incision adhesions in 6 of 7 monkeys treated with 10 mg/kg.
Achieved greater lesion volume reduction in monkeys without antidrug antibodies (ADAs) than those with ADAs.
CXCL8/IL-8
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
SMILES
[AMY109]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
AMY109 Related Classifications
HY-P992035 Related Classifications
Powered by Bioz